0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessBackground REACH and REACH-2 investigated ramucirumab in patients with HCC after sorafenib. An exploratory analysis of outcomes by Barcelona Clinic Liver Cancer (BCLC) stage was performed.
Matthias Pinter, Masatoshi Kudo, RS Finn, M Morimot, K.-M. Rau, Masafumi Ikeda, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Howard J. Lim, Khoon Lin Ling, Kazuko Yamaguchi‐Shinozaki, Reigetsu Yoshikawa, C Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu (2020). Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2). Zeitschrift für Gastroenterologie, DOI: 10.1055/s-0040-1712319.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2020
Authors
18
Datasets
0
Total Files
0
Language
English
Journal
Zeitschrift für Gastroenterologie
DOI
10.1055/s-0040-1712319
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
